Further Studies Clause Samples

The "Further Studies" clause requires the parties to undertake additional investigations, analyses, or research as necessary to fulfill the objectives of the agreement. In practice, this clause may obligate one or both parties to gather more information, conduct technical studies, or perform due diligence on specific aspects of the project or transaction. Its core function is to ensure that all relevant facts and data are obtained to support informed decision-making and to address any uncertainties that may arise during the course of the agreement.
POPULAR SAMPLE Copied 1 times
Further Studies. In the event that RPRP and Introgen agree that there are preclinical and/or clinical studies that may be mutually beneficial with respect to obtaining approval for any Collaboration Products outside North America. Introgen and RPRP may agree to conduct such studies jointly, on mutually agreed terms.
View SourceView Similar (4)
Further Studies. Studies on possible improvements are requested in Recommendation No. 4.
View SourceView Similar (3)
Further Studies. The Company agrees to carry out appropriate studies of the possible development of selected bauxite ore reserves within the Mining Area, which are presently classified as non-commercial.
View SourceView Similar (2)
Further Studies. ‌ The solver used in this study is still being developed and we believe that the solution obtained so far can be improved when the solver is completed. Further studies would there be required to analyse the costs associated when the vessel types are used for the transportation of products. Another area which has to be studied is the type of contract to be used. The choice of contract would be to put most vessels under Time charter and the remaining under Contract of affreightment. The Spot market should be avoided if possible or only a few vessels taken from the spot market. Due to time constrain on this study, some areas which were left out such as the use of vessels with increased capacity and the inventory routing problem can also be analysed in later studies. Appendix‌ Appendix A: product ranges/fraction available at production sites ASKOY TAU JELSA ARDAL DIRDAL DIMMELSVIK 2-5 2-5 2-5 8-16 0-32 8-16 5-8 5-8 8-11 0-2 0-22 0-8 8-11 8-11 8-16 0-4 16-32 0-32 8-16 8-16 11-16 0-8 5" 16-22 ▇▇-▇▇ ▇▇-▇▇ ▇-▇▇ ▇▇-▇▇ ▇▇-▇▇▇ ▇▇-▇▇ ▇▇-▇▇ ▇-▇▇ 0-32 SAND 50-120 SAND 0-16 0-16 0-5 VOLLYBALLSAND KONSTRUKSJON 0-32 0-2 20-120 32-63 0-22 5-16 0-5 0-32 5-11 32-64 0-8 5-8 0-11 16-32 3-64 ▇▇-▇▇ ▇▇-▇▇ 0-125 AB 16 5-16 AGB 16 20-120 GRØFTEPUKK 16-22 0-4 GRØFTEPUKK Reference‌
View Source
Further Studies 
View Source

Related to Further Studies

  • Further steps Each Party must promptly do whatever any other Party reasonably requires of it to give effect to the Agreement and to perform its obligations under it.

  • Further Negotiations In case where a Party offers, after the entry into force of this Agreement, to non-Party additional advantages with regard to its government procurement market access coverage agreed under this Chapter, it shall agree, upon request of the other Party, to enter into negotiations with a view to extending coverage under this Chapter on a reciprocal basis.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Further Actions Each party agrees to perform such further acts and execute such further documents as are necessary to effectuate the purposes hereof.

  • Research Program The term “